VEEP Treatment for Children with Hodgkin's Disease
Author Information
Author(s): M.E.R. O'Brien, C.R. Pinkerton, J. Kingston, M. Mott, D. Tait, S. Meller, M. Radford, J. Malpas, T.J. McElwain
Primary Institution: The Royal Marsden Hospital
Hypothesis
Can an anthracycline-based regimen without alkylating agents reduce late sequelae in children with Hodgkin's disease while maintaining remission rates?
Conclusion
The VEEP regimen shows promising response rates in children with Hodgkin's disease, but further follow-up is needed to assess long-term outcomes.
Supporting Evidence
- The response rate in previously treated patients was 80%.
- The response rate in untreated patients was 88%.
- 67% relapse-free rate at 3 years was observed.
- Median follow-up for all patients was 25 months.
Takeaway
Doctors are trying a new treatment for kids with Hodgkin's disease that might help them get better without causing other health problems later.
Methodology
Children aged 2-15 with Hodgkin's disease were treated with the VEEP regimen, which includes vincristine, epirubicin, etoposide, and prednisolone, at 3-week intervals.
Limitations
The study is a pilot with a small sample size and requires longer follow-up to confirm results.
Participant Demographics
Patients aged 2-15 years, with a mix of previously treated and untreated cases.
Statistical Information
Confidence Interval
95% CI 44-97%
Want to read the original?
Access the complete publication on the publisher's website